Short Interest in Molecular Partners AG (NASDAQ:MOLN) Grows By 70.4%

Molecular Partners AG (NASDAQ:MOLN) saw a significant increase in short interest in October. As of October 31st, there was short interest totalling 57,100 shares, an increase of 70.4% from the October 15th total of 33,500 shares. Based on an average daily trading volume, of 16,300 shares, the days-to-cover ratio is presently 3.5 days.

Molecular Partners Price Performance

Shares of NASDAQ:MOLN traded down $0.18 during midday trading on Wednesday, reaching $5.51. The company’s stock had a trading volume of 32,078 shares, compared to its average volume of 22,180. Molecular Partners has a fifty-two week low of $3.32 and a fifty-two week high of $12.70. The company has a market capitalization of $202.16 million, a P/E ratio of -2.56 and a beta of 0.98. The business’s fifty day simple moving average is $5.38 and its 200-day simple moving average is $5.60.

Molecular Partners (NASDAQ:MOLN) last announced its quarterly earnings data on Monday, August 26th. The company reported ($0.51) EPS for the quarter. The firm had revenue of $1.72 million during the quarter. Molecular Partners had a negative return on equity of 39.31% and a negative net margin of 1,043.01%. On average, analysts forecast that Molecular Partners will post -2.02 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Leerink Partnrs upgraded Molecular Partners to a “strong-buy” rating in a research note on Monday, October 7th.

Molecular Partners Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia.